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i.org/1in the general population. Recent data conﬁrm the prognostic utility of single-photon
emission computed tomographic (SPECT) imaging in end-stage renal disease, but whether
performing CACS as part of hybrid imaging improves risk prediction in this population is
unclear. Consecutive patients (n[ 284) were identiﬁed after referral to a university hospital
for cardiovascular risk stratiﬁcation in assessment for renal transplantation. Participants
underwent technetium-99m SPECT imaging after exercise or standard adenosine stress in
those unable to achieve 85% maximal heart rate; multislice CACS was also performed
(Siemens Symbia T16, Siemens, Erlangen, Germany). Subjects with known coronary artery
disease (n[ 88) and those who underwent early revascularization (n[ 2) were excluded.
The primary outcome was a composite of death or ﬁrst myocardial infarction. An abnormal
SPECT perfusion result was seen in 22% (43 of 194) of subjects, whereas 45% (87 of 194) had
at least moderate CACS (>100 U). The frequency of abnormal perfusion (summed stress
score ‡4) increased with increasing CACS severity (p [ 0.049). There were a total of 15
events (8 deaths, and 7 myocardial infarctions) after a median duration of 18 months
(maximum follow-up 3.4 years). Univariate analysis showed diabetes mellitus (Hazard ratio
[HR] 3.30, 95%CI 1.14 to 9.54; p[ 0.028), abnormal perfusion on SPECT (HR 5.32, 95%CI
1.84 to 15.35; p[ 0.002), andmoderate-to-severe CACS (HR 3.55, 95%CI 1.11 to 11.35; p[
0.032) were all associated with the primary outcome. In a multivariate model, abnormal
perfusion on SPECT (HR 4.18, 95% CI 1.43 to 12.27; p[ 0.009), but not moderate-to-severe
CACS (HR 2.50, 95% CI 0.76 to 8.20; p[ 0.130), independently predicted all-cause death or
myocardial infarction. The prognostic value of CACS was not incremental to clinical and
SPECT perfusion data (global chi-square change [ 2.52, p [ 0.112). In conclusion, a
perfusion defect on SPECT is an independent predictor of adverse outcome in potential renal
transplant candidates regardless of the CACS. The use of CACS as an adjunct to SPECT
perfusion data does not provide incremental prognostic utility for the prediction of mortality
and nonfatal myocardial infarction in end-stage renal disease.  2016 The Authors.
Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/). (Am J Cardiol 2016;117:1387e1396)Renal transplantation remains the most successful and
cost-effective treatment for patients with end-stage renal
disease (ESRD), signiﬁcantly improving cardiovascularardio-Renal Group, Department of Cardiology, Institute
Sciences, Nufﬁeld House, Queen Elizabeth Hospital
aston; and bDepartment of Cardiac Imaging and Nuclear
ark Taper Foundation Imaging Center Los Angeles,
cript received November 2, 2015; revised manuscript
pted February 8, 2016.
oody is supported by a British Heart Foundation Clin-
owship (FS/11/17/28700).
for disclosure information.
g author: Tel: (þ44) (0)-121-371-6130; fax: (þ44) (0)-
s: william.moody@nhs.net (W.E. Moody).
see front matter  2016 The Authors. Published by
is an open access article under the CC BY license (http://
org/licenses/by/4.0/).
0.1016/j.amjcard.2016.02.003(CV) outcomes compared with maintenance dialysis.1 Even
after transplantation, however, patients remain at high risk of
long-term CV complications. To ensure that graft survival is
not limited by premature CV death, both US and UK regu-
latory bodies recommend noninvasive CV assessment of
those transplant candidates with multiple risk factors or
diabetes, although there is no clear guidance on which im-
aging method to use.2,3 The current suggestion is to adopt an
imaging protocol for CV risk stratiﬁcation according to “best
local expertise.” Accordingly, many transplant centers
continue to use stress myocardial perfusion scintigraphy
because of longstanding data supporting its prognostic utility
in ESRD.4e7 Despite this, myocardial perfusion scintigraphy
has poor positive predictive value for identifying coronary
artery stenosis on invasive angiography.5,8 Moreover, it is
not able to detect subclinical atherosclerosis, potentiallywww.ajconline.org
Figure 1. Study consort diagram. *Six of 88 subjects (7%) excluded from the analysis because of previous coronary atheroma, PCI, or CABG underwent early
revascularization. Two further subjects without a baseline diagnosis of coronary atheroma underwent early revascularization (1 percutaneous coronary
intervention and 1 coronary artery bypass graft surgery) driven by the SPECT/CT result.
1388 The American Journal of Cardiology (www.ajconline.org)predisposing the patient in the longer term to subsequent
obstructive CV events. Hybrid single-photon emission
computed tomographic (SPECT)/CT imaging offers an
attractive opportunity to combine anatomic measures of
coronary artery calciﬁcation alongside a functional assess-
ment of myocardial ischemia. Coronary artery calcium score
(CACS) is a surrogate marker of atherosclerotic burden and a
strong predictor of adverse CV events in subjects at inter-
mediate risk from the general population.9 The predictive
role of CACS in subjects with ESRD, however, is less
certain.10,11 Despite the very high burden of coronary
calciﬁcation in this population, there is only a modest asso-
ciation between CACS and perfusion defects.12,13 In the
present study, we hypothesize that CACS will provide an
incremental beneﬁt for the prediction of death and ﬁrst
myocardial infarction (MI) in patients with ESRD beyond
that provided by perfusion defect scores on myocardial
perfusion imaging.Methods
Consecutive patients with chronic kidney disease (CKD)
stage 4 to 5D were identiﬁed after referral to Queen Eliz-
abeth Hospital Birmingham for CV risk stratiﬁcation as part
of a pretransplant screening work-up from January 2011 to
December 2013. In accordance with current guidelines
compiled by a Joint Working Party of The British Trans-
plantation Society and The Renal Association,3 subjects
were referred for noninvasive CV risk assessment if they
fulﬁlled any of the following criteria: age 50years, dia-
betes, suspected angina, or known ischemic heart disease.
Those subjects with a history of MI, coronary atheroma or
stenosis on angiography, or previous percutaneous or sur-
gical revascularization were excluded from the present study
(Figure 1). Formal ethical approval was not required
because this study was a retrospective assessment of solely
clinical data and was therefore regarded as a health out-
comes evaluation. The conduct and reporting of this studywas guided by the Strengthening the Reporting of Obser-
vational Studies in Epidemiology statement.14
Demographic and anthropometric data were collected on
all patients through review of patient electronic records. In
addition, a standard prescan assessment involving a detailed
patient interview was performed to obtain information on
symptoms, CV risk factors, previous CV events, and
medication. A Duke pretest probability of coronary artery
disease (CAD) was calculated at the time of the imaging
study.15 Routine hematology and biochemistry at the time of
the test were also recorded. Diabetes mellitus (DM) was
deﬁned as a fasting glucose >126 mg/dl, history of DM,
diabetic nephropathy, or currently receiving hypoglycemic
treatment. Hypertension was deﬁned as an ofﬁce blood
pressure >140/90 mm Hg or currently taking antihyper-
tensive medication. Hypercholesterolemia was deﬁned as a
serum cholesterol of >193 mg/dl or currently taking lipid
reduction therapy. A history of CV disease was deﬁned as
having any of the following: CAD (MI, previous percuta-
neous, or surgical revascularization), heart failure, stroke,
and peripheral vascular disease. Signiﬁcant family history of
CV disease was deﬁned as a ﬁrst degree relative with a
history of MI or ischemic stroke in men younger than
55 years and in women younger than 65 years.
Patients were asked to discontinue b blockers, rate-
limiting calcium channel blockers, and caffeine products
24 hours before testing, and nitrate compounds were dis-
continued >6 hours before testing. All participants under-
went 2-day stress-rest technetium-99m SPECT imaging
with exercise treadmill or standard adenosine stress (140 mg/
kg/min for 6 minutes) in those unable to achieve 85%
maximal heart rate; and multislice CACS was performed as
routine. CT-based attenuation correction was performed in
all patients during reconstruction of the SPECT data
(Symbia T16, Siemens, Erlangen, Germany).
SPECT myocardial perfusion images were visually
analyzed by 2 experienced observers (RPS andBH) blinded to
outcome variables (Quantitative Perfusion SPECT; Hermes
Coronary Artery Disease/Prognostic Value of CACS in ESRD 1389Medical Solutions, Stockholm, Sweden). In addition to ex-
amination of raw images in cine mode, both nonattenuated
and attenuated images were reviewed, and a report produced
consistent with recommendations outlined in the American
Society of Nuclear Cardiology Imaging Guidelines for Nu-
clear Cardiology Procedures.16 Short-axis and vertical long-
axis tomograms were divided into 17 segments for each
study,16 and segmental tracer uptake was evaluated using a
validated semiquantitative 5-point scoring system (0, normal;
1, equivocal; 2, moderate; 3, severe reduction of radioisotope
uptake; and 4, absence of detectable tracer uptake).17 The
summed stress and rest scores were obtained by adding the
scores of the 17 segments of the respective images. The sumof
the differences between each of the 17 segments from these
images was deﬁned as the summed difference score, repre-
senting the amount of ischemia. These indexes were con-
verted to the percentage of total myocardium involved with
stress, ischemic, or ﬁxed defects by dividing the summed
scores by 68 (the maximum potential score ¼ 4  17) and
multiplying by 100. The presence of abnormal perfusion was
deﬁned as a summed stress score of 4 or greater.18 A stress-
induced total perfusion defect size (PDS) >15% or an
ischemic PDS >10% deﬁned high risk for cardiac events.19
Cardiac volumes and left ventricular (LV) ejection fraction
were also calculated from the gated SPECT images.
The CACS was calculated according to Agatston et al20
by the same 2 independent observers blinded again to
outcome data. Lesions were manually traced on CT images
before semiautomatic quantiﬁcation-derived vessel-speciﬁc
scores were summated to yield the total CACS (syngo.via;
Leonardo; Siemens Medical Solutions, Forchheim, Ger-
many). Minimal, mild, moderate, and severe coronary
calciﬁcation were deﬁned as Agatston scores of 0 to 10 U,
11 to 100 U, 101 to 400 U, and >400 U, respectively.19
The primary outcome was a composite of all-cause death
or MI. Myocardial infarction was deﬁned as a clinical (or
pathologic) event caused by myocardial ischemia where
there is evidence of myocardial injury or necrosis as deﬁned
by an increase and/or decrease of cardiac biomarkers in the
presence of typical symptoms or electrocardiographic
changes, or imaging evidence of new loss of viable
myocardium or new regional wall motion abnormality.21
Patients who had revascularization within 90 days of the
imaging study were identiﬁed and excluded from the anal-
ysis to avoid inclusion of outcomes that may have been
driven temporally by the SPECT/CT result.6 The event of
all-cause death was examined separately as a secondary
outcome. Patients who underwent renal transplant surgery
during the study period were also identiﬁed.
Patient follow-up data were retrieved by an observer
blinded to the clinical and imaging data (WEM). Every patient
in the National Health Service has a unique identiﬁer which
enables outcomes to be tracked using the Hospital Episodes
Statistics (HES) database, an administrative data warehouse
containing admissions to all National Health Service hospitals
in England.22 It contains detailed records relating to individ-
ual patient treatments, with data extraction facilitated using
codes on procedural classiﬁcations (Ofﬁce of Population
Censuses and Surveys Classiﬁcation of Interventions and
Procedures, Fourth revision) and medical classiﬁcations
(World Health Organization International Classiﬁcation ofDisease, Tenth revision).23,24 With regard to outcome anal-
ysis, HES data alone have the limitation of only capturing
deaths occurring in a hospital setting. To obtain the complete
mortality list, the study cohort was also cross-referenced with
mortality data from the Ofﬁce for National Statistics, which
collects information on all registered deaths in the UK. All
outcomes were further veriﬁed by cross-referencing with in-
dividual hospital case notes held electronically.
Statistical analyses were performed with Stata, version
12 (StataCorp LP, College Station, Texas) and SAS (Sta-
tistical Analysis System, SAS Institute Inc., Cary, North
Carolina). Data are expressed as mean  SD, median
(interquartile range), or frequency (%), unless otherwise
stated. The normality of distribution for continuous vari-
ables was determined using normality plots and the Kol-
mogoroveSmirnov test. Baseline characteristics of the
population were examined by CACS category and SPECT
results. The KruskaleWallis analysis of variance was used
to identify signiﬁcant differences in central tendencies of
continuously scaled variables between groups. Contingency
table analysis was performed using the chi-square or
Fisher’s exact tests where appropriate.
Annualized event rates are expressed as the number of
patients having ﬁrst MI or all-cause death as a proportion of
the number of patients at risk divided by the number of
patient-years follow-up. KaplaneMeier analysis of out-
comes were based on discrete CACS categories (0 to 10, 11
to 100, 101 to 400, and >400 U) and SPECT categories
(normal, total LV PDS dichotomized at 15%, ischemic PDS
dichotomized at 10%). The date of the imaging test was
used as time zero. In view of the beneﬁcial CV effects of
renal transplantation, those patients undergoing renal
transplantation were censored at the time of the procedure.25
Two-sided log-rank tests were used to determine signiﬁ-
cance. Univariate and multivariate Cox proportional hazards
models were used to identify the association between time-
to-event and baseline clinical characteristics, SPECT and
CACS results. Multivariate Cox regression analyses were
also repeated using follow-up data not censored for trans-
plantation. The change in the global chi-square statistic was
calculated to determine the incremental prognostic value of
clinical, SPECT, and CACS data. A p value <0.05 was
considered statistically signiﬁcant for all analyses.
Results
In total, 284 consecutive patients (CKD stage 4 to 5D)
with imaging performed from March 2011 to December
2013 were identiﬁed; of those, 88 had CAD at baseline. A
further 2 subjects without a previous diagnosis of coronary
atheroma underwent early revascularization (1 coronary
artery bypass graft surgery and 1 percutaneous coronary
intervention) after SPECT demonstrated a reversible PDS
10%, leaving 194 subjects available for inclusion in the
present analysis (Figure 1).
The baseline characteristics of the study cohort are
summarized in Table 1. Mean age was 56 years, 60% were
men, 33% were diabetic, and 82% were hypertensive. Most
patients were asymptomatic (75%). Two-thirds of patients
had at least mild CACS (65%), and over a quarter had se-
vere CACS (27%). In those with an abnormal SPECT result
Table 1
Baseline demographics and clinical characteristics for study cohort
Variable n ¼ 194
Age (years) 56.3  10.2
Male 117 (60%)
White 128 (66%)
Asian 49 (25%)
Afro-Caribbean 12 (6%)
Other ethnicity 4 (2%)
Body mass index (kg / m2) 27.5  5.0
Diabetes mellitus 64 (33%)
Hypertension* 159 (82%)
Hypercholesterolemia† 133 (69%)
Current smoker 36 (19%)
Family history of coronary artery
disease
38 (20%)
Number of cardiac risk factors 2.3  1.0
Duke pre-test probability (%) 5 (3 e 8)
Symptomatic chest pain 48 (25%)
Typical angina / atypical /
non-cardiac
10 (5%) / 20 (10%) / 18 (9%)
Hemoglobin (g/ L) 111  16
Total cholesterol (mg / dL) 185  46
Calcium (mg / dL) 9.00  0.64
Phosphate (mg / dL) 4.30  1.24
Parathyroid hormone, (median pg / mL
[IQR])
21.8 (13.1 e 39.9)
Uric acid (mg / dL) 7.13  1.98
CACS (median Agatston units [IQR]) 52 (0 e 509)
CACS severity
0 e 10 68 (35%)
11 e 100 39 (20%)
101 e 400 35 (18%)
>400 52 (27%)
Ability to perform exercise stress 112 (58%)
METS achievedz 6.7  3.4
Stress electrocardiogram result
Normal / Equivocal / Abnormal
130 (67%) / 39 (20%) / 25 (13%)
Left ventricular ejection fraction
(median % [IQR])
56 (50 e 62)
Abnormal SPECTx 43 (22%)
Total perfusion deﬁcit score (% LV) 3.9  8.9
Ischemic perfusion deﬁcit score (%LV) 1.6  3.8
Total perfusion deﬁcit score  15% 18 (9%)
Ischemic perfusion deﬁcit score 10% 13 (7%)
Medications
Aspirin 71 (37%)
Thienopyridine 9 (5%)
Beta-blocker 79 (41%)
ACE inhibitor / angiotensin
receptor blocker
86 (44%)
Calcium channel blocker 97 (50%)
Loop diuretic 66 (33%)
Statin 123 (63%)
Insulin 42 (22%)
Data are number (%) or mean  SD unless otherwise stated.
ACE ¼ angiotensin-converting enzyme; CACS ¼ coronary artery calcium
score; IQR ¼ interquartile range; LV ¼ left ventricular; METS ¼ metabolic
equivalents of task; SPECT¼ single-photon emission computed tomography.
* Deﬁned as an ofﬁce blood pressure of >140/90 mm Hg or currently
taking antihypertensive medications.
† Deﬁned as a fasting serum cholesterol of >193 mg/dl or currently
taking lipid reduction therapy.
z In the 112 subjects capable of treadmill exercise.
x Deﬁned as a summed stress score of 4.
1390 The American Journal of Cardiology (www.ajconline.org)(28%), almost half (42%) had a total PDS 15% and a third
(30%) had an ischemic PDS 10%.
Patients with a large total or ischemic PDS were older,
less likely to be able to perform exercise treadmill stress and
more likely to have accompanying LV dysfunction
(Table 2). There was no difference in the mean number of
cardiac risk factors between subjects with a normal SPECT
result and those with a large perfusion defect.
As depicted in Table 3, subjects with a higher CACS were
older and more frequently men and diabetic. There was a
graded association between increasing CACS and worsening
LV function. Therewas no signiﬁcant association between the
frequency of symptomatic chest pain and CACS severity.
Subjects with a normal SPECT result had a lower median
Agatston score compared to those with abnormal perfusion
(35 U [IQR 0 to 349 U] vs 306 U [IQR 14 to 912 U]; p
<0.01). There was a weak-graded association between the
increasing proportion of patients with abnormal perfusion
and increasing CACS severity (p ¼ 0.049; Figure 2). There
was, however, no signiﬁcant association between CACS
severity and the frequency of a large stress-induced total
(10%) or ischemic (10%) PDS. An abnormal SPECT
result was observed in 12% of subjects (8 of 68) with a
CACS 0 to 10 and in 23% of subjects (9 of 39) with a CACS
11 to 100 U. In 4% of patients with only minimal CACS (3
of 68), a high-risk SPECT proﬁle was demonstrated based
on the stress-induced total PDS.
There were a total of 15 primary events (8 deaths and 7
MIs) after a median duration of 18 months (maximal follow-
up 3.4 years). Forty-one patients (21%) underwent renal
transplantation during the study period, one of whom died.
This posttransplant death occurred 3 months after surgery in
a subject with hypertension and type 2 DM; SPECT/CT
imaging had demonstrated severe CACS (2,376 U) but no
evidence of a perfusion defect. Two further patients who
underwent transplant suffered a nonfatal MI, 1 subject with
severe CACS >400 U and 1 subject with a detectable
perfusion defect.
Univariate predictors of the primary outcome were DM,
abnormal perfusion on SPECT, and an Agatston score of
>100 U (all p <0.05; Table 4). In a multivariate model,
abnormal perfusion on SPECT and diabetes, but not CACS
independently predicted all-cause death/nonfatal MI. The
results from multivariate Cox regression analyses performed
using data not censored for transplantation showed no sig-
niﬁcant difference in the models shown (data not shown).
The risk for all-cause death/nonfatal MI increased
signiﬁcantly with the presence and extent of SPECT
abnormality (Figure 3) and with the presence of moderate-
to-severe CACS (Figure 4). In subjects with abnormal
perfusion by SPECT (summed stress score 4), the annu-
alized event rate for the primary outcome of all-cause death/
nonfatal MI was 13.8% versus 2.8% in those with normal
perfusion. Similarly, the incident rate of all-cause death/
nonfatal MI was 12.8% for those subjects with moderate-to-
severe CACS compared with 7.6% in those with a CACS
<100 U. The value of integrating SPECT and CACS results
for risk prediction is depicted in Figure 5.
The incremental value of CACS and stress SPECT re-
sults to predict the primary event over clinical data by global
chi-square analysis is depicted in Figure 6. There was a
Table 2
Baseline demographics, clinical characteristics, and stress test differences by single-photon emission computed tomography results (n ¼ 194)
Variable Normal
(n ¼ 151)
PDS <15%
(n ¼ 25)
PDS 15%
(n ¼ 18)
p Value* IPDS <10%
(n ¼ 30)
IPDS 10%
(n ¼ 13)
p Value†
Age 56.0  10.2 53.9  10.7 62.8  7.3 0.01 54.8  10.0 65.0  8.1 <0.01
Male 88 (58%) 20 (80%) 8 (44%) 0.046 22 (73%) 7 (54%) 0.27
Diabetes mellitus 46 (31%) 15 (60%) 7 (39%) 0.02 10 (33%) 7 (54%) 0.22
Hypertension 124 (82%) 21 (84%) 13 (72%) 0.56 26 (87%) 8 (64%) 0.14
Hypercholesterolemia 104 (69%) 17 (68%) 12 (67%) 0.98 20 (67%) 9 (73%) 0.97
Smoker 71 (47%) 11 (44%) 8 (44%) 0.95 15 (50%) 5 (36%) 0.78
Number of risk factors 2.3  0.1 2.4  1.0 2.4  1.4 0.55 2.4  1.0 2.3  1.5 0.66
Duke pre-test probability (%) 6 (3 e 8) 5 (3 e 8) 7 (3 e 18) 0.01 4 (3 e 7) 10 (4 e 20) 0.02
Symptomatic chest pain 35 (23%) 8 (32%) 5 (28%) 0.61 8 (27%) 5 (36%) 0.46
Ability to perform exercise stress 96 (64%) 11 (44%) 5 (28%) <0.01 13 (43%) 3 (23%) <0.01
LV ejection fraction (%) 57 (51 e 63) 55 (50 e 60) 46 (29 e 51) <0.001 51 (45 e 57) 50 (34 e 61) <0.001
Data are number (%), mean  SD or median (interquartile range).
IPDS ¼ ischemic perfusion defect size; PDS ¼ perfusion defect size.
* Normal SPECT versus total PDS <15%, total PDS 15%.
† Normal SPECT versus ischemic PDS <10%, ischemic PDS 10%.
Table 3
Baseline demographics, clinical characteristics, and stress test differences by coronary artery calcium score severity
Variable CACS Severity Groups (n ¼ 194)
0 e 10
(n ¼ 68)
11 e 100
(n ¼ 39)
101 e 400
(n ¼ 35)
>400
(n ¼ 52)
P Value
Age (years) 51.8  11.5 58.5  7.6 58.1  7.9 59.1  9.6 <0.001
Male 29 (43%) 26 (67%) 21 (60%) 42 (79%) <0.001
Diabetes mellitus 15 (22%) 12 (31%) 18 (51%) 19 (36%) 0.02
Hypertension 59 (87%) 33 (85%) 26 (74%) 42 (79%) 0.44
Hypercholesterolemia 46 (68%) 25 (64%) 25 (71%) 37 (70%) 0.88
Smoker 29 (43%) 22 (56%) 15 (43%) 24 (45%) 0.55
Number of risk factors 2.2  1.0 2.4  1.0 2.5  1.0 2.3  1.0 0.50
Duke pre-test probability (%) 4 (2 e 5) 5 (4 e 8) 5 (3 e 8) 7 (4 e 9) 0.06
Symptomatic chest pain 24 (35%) 11 (28%) 7 (20%) 8 (15%) 0.07
Ability to perform exercise stress 44 (65%) 23 (59%) 20 (57%) 26 (49%) 0.45
LV ejection fraction (%) 57 (54 e 64) 58 (49 e 62) 57 (48 e 64) 53 (44 e 59) 0.047
Data are number (%), mean  SD or median (interquartile range).
Coronary Artery Disease/Prognostic Value of CACS in ESRD 1391signiﬁcant improvement in risk prediction with the addition
of abnormal perfusion on SPECT to clinical information
(chi-square change ¼ 8.06, p ¼ 0.005). The prognostic
value of CACS was not incremental to clinical and SPECT
perfusion data (global chi-square change ¼ 2.52, p ¼
0.112).
Discussion
This study suggests that quantiﬁcation of CACS along-
side SPECT imaging does not provide incremental prog-
nostic utility for prediction of mortality and nonfatal MI in
potential renal transplant candidates. SPECT imaging
continued, however, to be a useful method in identifying
those subjects with ESRD at high CV risk. In those with
abnormal perfusion, the risk for all-cause death/nonfatal MI
increased signiﬁcantly with the presence and extent of
SPECT abnormality. Although a CACS >100 U was
associated with a worse outcome, the presence of moderate-
to-severe CAC did not independently predict outcome afteradjusting for clinical data and the SPECT perfusion result.
Most patients with ESRD had at least mild coronary calci-
ﬁcation (CACS >10 U), but there was a signiﬁcant pro-
portion (12%) with only minimal CAC who had an
abnormal SPECT perfusion result, which continued to
confer a higher event rate. This ﬁnding demonstrates that the
absence of CAC does not eliminate the potential for
obstructive CAD in ESRD.
Our study is the ﬁrst to identify that abnormal perfusion
is the more important factor in identifying adverse CV event
rates in ESRD relative to the impact of CACS. One previous
study in 411 patients with ESRD (86% dialysis dependent)
identiﬁed a modest association between increasing CACS
and abnormal perfusion, as found in our study, but did not
examine the association with clinical outcomes.13 In general
population subjects without advanced CKD, there are con-
ﬂicting reports regarding the ability of hybrid imaging to
predict CV outcomes. Our data are consistent with those of
Rozanski et al26 which suggest that when perfusion is
normal, elevated CACS does not confer an increased risk of
Figure 2. Relation between CACS and SPECT results. Relation between CACS severity and stress SPECT results (n ¼ 194). The percentage of subjects with an
abnormal SPECT result signiﬁcantly increased with increasing CACS severity (p ¼ 0.049). There was no signiﬁcant association between the frequency of a
large stress-induced total (>15%) or ischemic (>10%) LV perfusion defect and CACS severity. Twelve percent of subjects with minimal CACS (8 of 68) had
abnormal perfusion on SPECT.
Table 4
Univariate and multivariate predictors of events
Variable Death or Non-fatal Myocardial Infarction All-cause Mortality
Univariate Analysis Multivariate Analysis Univariate Analysis Multivariate Analysis
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Age 0.99 (0.95 - 1.05) 0.829 0.98 (0.92 - 1.04) 0.463
Gender (female) 0.85 (0.29 - 2.44) 0.758 0.37 (0.09 - 1.55) 0.173
Diabetes 3.30 (1.14 - 9.54) 0.028 2.57 (0.87 - 7.59) 0.088 2.46 (0.61 - 9.87) 0.203 1.99 (0.48 - 8.20) 0.339
Current smoker 2.21 (0.74 - 6.62) 0.155 4.34 (1.08 - 17.41) 0.038
Hypercholesterolemia 0.63 (0.22 - 1.81) 0.390 0.79 (0.19 - 3.31) 0.746
LV ejection fraction < 55%* 2.44 (0.84 - 7.05) 0.099 3.20 (0.76 - 13.42) 0.112
Ability to exercise 0.31 (0.10 - 0.98) 0.046 0.45 (0.11 - 1.89) 0.275
Abnormal perfusion† 5.32 (1.84 - 15.35) 0.002 4.18 (1.43 - 12.27) 0.009 5.32 (1.84 - 15.35) 0.002 3.00 (0.72 - 12.46) 0.131
At least moderate CACSz 3.55 (1.11 - 11.35) 0.032 2.50 (0.76 - 8.20) 0.130 2.23 (0.53 - 9.4) 0.273 1.62 (0.37 - 7.13) 0.524
Multivariate regression models were adjusted for age, gender, and diabetes.
* Deﬁned by gated single-photon emission computed tomography imaging.
† Deﬁned as summed stress score 4.
z Deﬁned as coronary artery calcium score >100 U.
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with intermediate risk, abnormal perfusion was associated
with adverse CV events even in those subjects with no
calciﬁcation, albeit with a lower event rate than in those
subjects with higher CACS.27 However, in a study of 1,126
largely asymptomatic patients, after a much longer duration
of follow-up (median 6.9 years), Chang et al were able to
demonstrate that CACS offered incremental risk predictionin subjects with a normal perfusion result.19 The relative
increase in all-cause death/MI was limited to those with
CACS >400 U and survival curves only began separating
after 3 years, raising the possibility that the impact of CACS
on outcome may only be seen after longer follow-up than in
our study.
A second possible explanation for the failure of CACS to
provide incremental risk predictive value over SPECT in the
Figure 3. KaplaneMeier curves comparing time to death or ﬁrst MI according to stress SPECT results: (A) Perfusion abnormality; (B) total PDS; and (C)
ischemic PDS. Two-sided log-rank tests were used to determine signiﬁcance.
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Figure 4. KaplaneMeier curves comparing time to death or ﬁrst MI according to the presence or absence of severe CACS. Two-sided log-rank tests were used
to determine signiﬁcance.
Figure 5. KaplaneMeier curves comparing time to death or ﬁrst MI according to integrated results of SPECT/CT. p Value shown corresponds to a signiﬁcance
difference between all 4 survival curves. There is also a signiﬁcant difference in the survival curves for “abnormal perfusion/CACS 100” and “abnormal
perfusion/CACS >100” (p <0.01). Two-sided log-rank tests were used to determine signiﬁcance.
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calciﬁcation in ESRD.11 One of the major uses of CACS in
the general population has been to identify those at very lowrisk by conﬁrming the absence of calciﬁcation,28 but pa-
tients with ESRD represent a different challenge. Our study
is consistent with others in identifying a remarkably high
Figure 6. Incremental predictive value of CACS and stress SPECT results over clinical information. The clinical data entered into the global chi-square analysis
model included age, gender, and the presence or absence of diabetes. Abnormality on SPECT (deﬁned as SSS >4) and at least moderate calciﬁcation (CACS
>100 U) were entered as binary variables.
Coronary Artery Disease/Prognostic Value of CACS in ESRD 1395prevalence of moderate and severe CACS, which may be a
consequence of other factors including abnormal cal-
ciumephosphate handling in ESRD rather than reﬂecting
atherosclerosis alone. Indeed, a strong correlation between
decreasing glomerular ﬁltration rate and increasing CACS
has been demonstrated, such that 3 of 4 subjects with ESRD
have a CACS above the 75th centile for gender-and age-
matched subjects without ESRD.29 Moreover, arterial
calciﬁcation in ESRD is not limited to the intima (athero-
sclerosis) causing obstructive coronary disease but also af-
fects the media (arteriosclerosis), which is associated with
pressure overload and heart failure.11 CACS using 16-slice
CT without noninvasive angiography is unable to discrim-
inate between intimal and medial calciﬁcation, which may
be a further factor contributing to the lack of data associ-
ating increasing CACS with an increased CV event rate in
ESRD.11
There are a number of limitations to our study. These
data are from consecutive patients but recruited from a
single center with retrospective analysis. The relatively
low number of events during follow-up that was limited to
a median of 18 months (maximum 3.4 years) may have
impacted on our ability to demonstrate an independent
association of CACS with hard clinical outcomes. By
combining HES with Ofﬁce for National Statistics data
sources, our data linkage process created a complete
dataset with regard to mortality. It is possible that events
may have been missed for those subjects admitted tohospital abroad, although it would be unusual for patients
on renal replacement therapy to leave the country,
particularly around the time of work-up for potential
transplant. Age did not appear to have a signiﬁcant in-
ﬂuence on adverse outcomes in this cohort. This ﬁnding
may in part, reﬂect the relatively narrow age range of our
population. There are data that demonstrate traditional CV
risk factors are very poor predictors of cardiac events in
ESRD.30 Annual CV mortality for those receiving main-
tenance hemodialysis is from 10 to 20 times that of the
general population, and younger adults have the greatest
increase in CV risk.1 Thus, time on maintenance dialysis
rather than age may be a more important factor in pre-
dicting adverse outcomes, and the lack of data on this
variable is an important limitation of our analysis.Disclosure
The authors have no conﬂicts of interest to disclose.
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